Fortrea Holdings Inc. (FTRE)vsModerna Inc (MRNA)
FTRE
Fortrea Holdings Inc.
$23.14
-10.61%
HEALTHCARE · Cap: $2.14B
MRNA
Moderna Inc
$222.76
+4.01%
HEALTHCARE · Cap: $85.50B
Smart Verdict
WallStSmart Research — data-driven comparison
Fortrea Holdings Inc. generates 20% more annual revenue ($2.68B vs $2.23B). FTRE leads profitability with a -3.2% profit margin vs -141.4%. FTRE earns a higher WallStSmart Score of 41/100 (D).
FTRE
Hold41
out of 100
Grade: D
MRNA
Avoid21
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-39.5%
Fair Value
$8.31
Current Price
$23.14
$14.83 premium
Margin of Safety
+69.9%
Fair Value
$134.71
Current Price
$222.76
$88.05 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Growing faster than its price suggests
Large-cap with strong market position
Conservative balance sheet, low leverage
Areas to Watch
Operating margin of 2.6%
Weak financial health signals
ROE of -85.0% — below average capital efficiency
Revenue declined 4.5%
Trading at 13.1x book value
2.1% revenue growth
Weak financial health signals
ROE of -46.6% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : FTRE
The strongest argument for FTRE centers on PEG Ratio. PEG of 0.34 suggests the stock is reasonably priced for its growth.
Bull Case : MRNA
The strongest argument for MRNA centers on Market Cap, Debt/Equity.
Bear Case : FTRE
The primary concerns for FTRE are Operating Margin, Piotroski F-Score, Return on Equity. Debt-to-equity of 2.13 is elevated, increasing financial risk.
Bear Case : MRNA
The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
FTRE carries more volatility with a beta of 1.91 — expect wider price swings.
MRNA is growing revenue faster at 2.1% — sustainability is the question.
FTRE generates stronger free cash flow (-26M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
FTRE scores higher overall (41/100 vs 21/100). MRNA offers better value entry with a 69.9% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Fortrea Holdings Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. The company is headquartered in Durham, North Carolina.
Visit Website →Moderna Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?